Advances in Brachytherapy in the Treatment of Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 11811
Special Issue Editor
Special Issue Information
Dear Colleagues,
Brachytherapy is the oldest and first successful radiotherapeutic procedure which continues to have the best dose distribution among all radiotherapy techniques even today if adequately used. Brachytherapy enables us to deliver a higher dose of radiation to a tumor than might be possible with conventional external radiation therapy while minimizing damage to the surrounding normal tissue. Therefore, brachytherapy is a fascinating procedure to destroy cancer cells in a broad type of cancers—prostate cancer, breast cancer, head and neck cancer, brain tumor, liver cancer, gynecological tumors such as cervical cancer, etc. With the advent of advanced imaging modality, brachytherapy has attracted increased attention in the 21st century. For instance, the EMBRACE project improved outcomes of cervical cancer using MRI images with the MRI-enabled applicator and interstitial implantation technique. In prostate cancer treatment, in addition to the LDR technique using ultrasound and CT images, the HDR technique widened its applicability using MRI imaging. Recent exploration of dominant intraprostatic lesion (DIL) boost has the potential to improve outcomes without elevating toxicity. Here, we welcome papers enhancing the role of brachytherapy in medicine.
Dr. Hideya Yamazaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brachytherapy
- LDR
- HDR
- PDR
- cervical cancer
- prostate cancer
- breast cancer